Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | FABP7 | O15540 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29602099 | 1.00 | KMT2A (0.61) | KMT2ASLC1A3SLC1A1EPHX2MDM4 | |
| SCHEMBL17746950 | 1.00 | KMT2A (0.61) | KMT2ASLC1A3SLC1A1EPHX2MDM4 | |
| SCHEMBL423641 | 1.00 | KMT2A (0.61) | KMT2ASLC1A3SLC1A1EPHX2MDM4 | |
| SCHEMBL30608469 | 1.00 | KMT2A (0.61) | KMT2ASLC1A3SLC1A1EPHX2MDM4 | |
| SCHEMBL16915228 | 1.00 | KMT2A (0.61) | KMT2ASLC1A3SLC1A1EPHX2MDM4 | |
| SCHEMBL17746952 | 0.93 | KMT2A (0.65) | KMT2ASLC1A3SLC1A1EPHX2MDM4 | |
| SCHEMBL17746951 | 0.93 | KMT2A (0.65) | KMT2ASLC1A3SLC1A1EPHX2MDM4 | |
| SCHEMBL30905448 | 0.93 | KMT2A (0.65) | KMT2ASLC1A3SLC1A1EPHX2MDM4 | |
| SCHEMBL2089280 | 0.92 | KMT2A (0.67) | KMT2ASLC1A3SLC1A1EPHX2MDM4 | |
| SCHEMBL10052316 | 0.92 | KMT2A (0.67) | KMT2ASLC1A3SLC1A1EPHX2MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612429-B2 | Derivatives of dolaproine-dolaisoleuine peptides | AGENSYS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20220204557-A1 | DERIVATIVES OF DOLAPROINE-DOLAISOLEUINE PEPTIDES | AGENSYS, INC. (US) | 2022-06-30 | — | — | US | disclosed |
| US-11312748-B2 | Derivatives of dolaproine-dolaisoleucine peptides | AGENSYS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204557-A1 | DERIVATIVES OF DOLAPROINE-DOLAISOLEUINE PEPTIDES | DDOST, VIP, THPO | KMT2A 4573/4885SLC1A3 3853/4885SLC1A1 4033/4885 |
| US-12612429-B2 | Derivatives of dolaproine-dolaisoleuine peptides | DDOST, NGLY1, GRPR | KMT2A 4768/4885SLC1A3 4061/4885SLC1A1 4086/4885 |
| US-11312748-B2 | Derivatives of dolaproine-dolaisoleucine peptides | VIP, DDOST, DNPEP | KMT2A 4773/4885SLC1A3 1484/4885SLC1A1 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.